
Nov 17, 2026 · 29 min
Listen from 23:46
Listen at 23:46
Biotech bets meet a pivotal FDA succession fight
Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton Odds
The episode connects risk-sharing in late-stage drug development, the limits of personalized cancer vaccines, and uncertainty over who may lead the FDA.
- 1J&J’s planned $2.2 billion Ollin acquisition tests whether China-sourced bispecific assets can justify late-stage development risk.
- 2Neoantigen vaccines face decisive questions about treatment timing, tumor types, clinical benefit, and manufacturing speed.
- 3Heidi Overton’s revived FDA nomination remains vulnerable to Senate opposition and competing plans for agency leadership.
Don't miss
The panel lays out the competing political pressures that revived Heidi Overton’s FDA nomination and could still derail it.
The brief
Johnson & Johnson plans to pay $2.2 billion for Ollin, a NewCo built around China-sourced VEGF/Ang2 bispecific assets for retinal disease. Blackstone helped distribute the risk of Phase 3 development.
The panel asks whether neoantigen vaccines can move beyond post-resection melanoma, weighing Merck and Moderna’s encouraging data against questions about monotherapy, earlier treatment, tumor types, and design.
Manufacturing may determine the modality’s reach as much as biology does: biopsy-to-treatment speed, differences among mRNA, DNA, and peptide vaccines, and decentralized production remain unresolved.
Steve Usdin explains how lobbying revived Heidi Overton’s FDA nomination, while disputes over vaping, mifepristone, and Republican support leave the Senate outcome uncertain.
If Overton fails, Sarah Brenner is emerging as the leading acting-commissioner candidate, but former FDA officials sharply disagree about whether she could stabilize the agency.
What was said on this episode
16 statements · 7 positive · 4 negative · 5 neutral
The Allen transaction includes more than $1.1 billion in regulatory and commercial milestones.
“There's another 1.1 or a little more. in regulatory and commercial milestones.”
Listen at 2:18
Allen’s VEGF/ANG2 bispecific appears to drive the acquisition.
“it looks like only one of them is really driving the deal.”
Listen at 2:38
Allen’s VEGF/ANG2 bispecific is scheduled to enter Phase 3 testing.
“it's in-licensed from Innovent, and it's set to enter phase three testing.”
Listen at 2:46
Merck and Moderna’s personalized neoantigen vaccine modality met a late-stage trial objective.
“this modality could meet in a late stage trial.”
Listen at 9:45
The neoantigen vaccine field likely needs several years for solid answers.
“we're probably still a ways out a couple years out from beginning to really get more solid answers to some of these questions”
Listen at 11:58
Moderna and Merck’s neoantigen program leads the pipeline with the most Phase 3 trials.
“they're still clearly ahead in the pipeline. They have the most phase three trials.”
Listen at 12:23
The Moderna and Merck program’s primary readout is not expected until 2028.
“this one's still not going to reach its primary readout till 2028.”
Listen at 12:30
BioNTech and Roche’s neoantigen program has struggled to demonstrate clinical efficacy.
“that has really struggled to show efficacy in the clinic, including as monotherapy plus Keytruda.”
Listen at 12:54
BioNTech and Roche’s Phase 3 trial failed its progression-free-survival endpoint.
“that failed to meet its progression-free survival endpoint.”
Listen at 13:15
Avaxion’s EVX01 study showed deepened responses, a 75% response rate, and four complete responses.
“the two-year results did show a deepening of response. above Keytruda with 75% objective response rate and four complete responses.”
Listen at 14:25
mRNA and DNA vaccines manufacture faster than peptide vaccines because peptides require separate synthesis.
“mRNA and DNA have faster manufacturing times because everything can be encoded on one strand of genetic material, whereas for peptides, it takes longer because... Everyone has to be synthesized separately.”
Listen at 16:30
Decentralized manufacturing is currently the biggest bottleneck for smaller vaccine developers.
“the biggest bottleneck right now is having decentralized manufacturing for smaller players.”
Listen at 16:51
The Trump administration had nearly abandoned efforts to confirm Heidi Overton as FDA commissioner.
“the Trump administration had all but given up on getting Heidi Overton confirmed as FDA commissioner.”
Listen at 17:55
The White House mobilized to preserve Heidi Overton’s FDA nomination.
“the White House mobilized to try to save the nomination.”
Listen at 18:01
Overton needs unanimous Republican HELP Committee support if all Democrats oppose her.
“if all the Democrats on that committee vote against her, Overton needs every Republican on the committee to vote yes.”
Listen at 18:56
Sarah Brenner is the leading contender for acting FDA commissioner if Overton is not confirmed.
“the leading contender for being acting commissioner of Overton isn't confirmed. It's Sarah Brenner.”
Listen at 25:24
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.